BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 9215091)

  • 1. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group.
    Patel R; Bodsworth NJ; Woolley P; Peters B; Vejlsgaard G; Saari S; Gibb A; Robinson J
    Genitourin Med; 1997 Apr; 73(2):105-9. PubMed ID: 9215091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group.
    Bodsworth NJ; Crooks RJ; Borelli S; Vejlsgaard G; Paavonen J; Worm AM; Uexkull N; Esmann J; Strand A; Ingamells AJ; Gibb A
    Genitourin Med; 1997 Apr; 73(2):110-6. PubMed ID: 9215092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group.
    Reitano M; Tyring S; Lang W; Thoming C; Worm AM; Borelli S; Chambers LO; Robinson JM; Corey L
    J Infect Dis; 1998 Sep; 178(3):603-10. PubMed ID: 9728526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group.
    Tyring SK; Douglas JM; Corey L; Spruance SL; Esmann J
    Arch Dermatol; 1998 Feb; 134(2):185-91. PubMed ID: 9487210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections.
    Ormrod D; Scott LJ; Perry CM
    Drugs; 2000 Apr; 59(4):839-63. PubMed ID: 10804039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.
    Johnston C; Saracino M; Kuntz S; Magaret A; Selke S; Huang ML; Schiffer JT; Koelle DM; Corey L; Wald A
    Lancet; 2012 Feb; 379(9816):641-7. PubMed ID: 22225814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.
    Fife KH; Warren TJ; Justus SE; Heitman CK;
    Sex Transm Dis; 2008 Jul; 35(7):668-73. PubMed ID: 18461016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group.
    Fife KH; Barbarash RA; Rudolph T; Degregorio B; Roth R
    Sex Transm Dis; 1997 Sep; 24(8):481-6. PubMed ID: 9293612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial.
    Fife KH; Warren TJ; Ferrera RD; Young DG; Justus SE; Heitman CK; Burroughs SM
    Mayo Clin Proc; 2006 Oct; 81(10):1321-7. PubMed ID: 17036557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections.
    Perry CM; Faulds D
    Drugs; 1996 Nov; 52(5):754-72. PubMed ID: 9118821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group.
    Spruance SL; Tyring SK; DeGregorio B; Miller C; Beutner K
    Arch Intern Med; 1996 Aug 12-26; 156(15):1729-35. PubMed ID: 8694673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients.
    Le Cleach L; Trinquart L; Do G; Maruani A; Lebrun-Vignes B; Ravaud P; Chosidow O
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009036. PubMed ID: 25086573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.
    Wald A; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Fife K; Selke S; Huang ML; Stobernack HP; Zimmermann H; Corey L; Birkmann A; Ruebsamen-Schaeff H
    JAMA; 2016 Dec; 316(23):2495-2503. PubMed ID: 27997653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials.
    Conant MA; Schacker TW; Murphy RL; Gold J; Crutchfield LT; Crooks RJ;
    Int J STD AIDS; 2002 Jan; 13(1):12-21. PubMed ID: 11802924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily valacyclovir to reduce the risk of transmission of genital herpes.
    Corey L; Wald A; Patel R; Sacks SL; Tyring SK; Warren T; Douglas JM; Paavonen J; Morrow RA; Beutner KR; Stratchounsky LS; Mertz G; Keene ON; Watson HA; Tait D; Vargas-Cortes M;
    N Engl J Med; 2004 Jan; 350(1):11-20. PubMed ID: 14702423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
    Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
    Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV.
    Warren T; Harris J; Brennan CA
    Clin Infect Dis; 2004 Nov; 39 Suppl 5():S258-66. PubMed ID: 15494897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir.
    Strand A; Patel R; Wulf HC; Coates KM;
    Sex Transm Infect; 2002 Dec; 78(6):435-9. PubMed ID: 12473805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes. Genival Study Group.
    Saiag P; Praindhui D; Chastang C
    J Antimicrob Chemother; 1999 Oct; 44(4):525-31. PubMed ID: 10588314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial.
    Abudalu M; Tyring S; Koltun W; Bodsworth N; Hamed K
    Clin Infect Dis; 2008 Sep; 47(5):651-8. PubMed ID: 18637755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.